113. Muscular dystrophy Clinical trials / Disease details

Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

18 trials found

diseases per page:

Showing 1 to 10 of 18 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-002069-52-IE (EUCTR)	11/12/2020	21/05/2019	A research study of a new investigational medicinal product for the treatment of Duchenne Muscular D ...	A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the E ...	Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping MedDRA version: 20.0;Le ...	Product Name: SRP-4045 Product Code: SRP-4045 INN or Proposed INN: Casimersen Other descriptive name: P ...	Sarepta Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	222	Phase 3	Serbia;United States;Taiwan;Greece;Spain;Ukraine;Ireland;Israel;Russian Federation;Italy;France;Denm ...
2	EUCTR2017-004625-32-BG (EUCTR)	03/12/2020	28/10/2020	A long-term extension study of a new investigational medicinal product for the treatment of Duchenne ...	Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clin ...	Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping MedDRA version: 20.0;Lev ...	Product Name: SRP-4045 Product Code: SRP-4045 INN or Proposed INN: CASIMERSEN Other descriptive name: P ...	Sarepta Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	150	Phase 3	United States;Czechia;Spain;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Belgium;Poland; ...
3	NCT04708314 (ClinicalTrials.gov)	October 31, 2020	21/9/2020	An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy	An Open-Label Study to Evaluate the Safety of Golodirsenin Non-Ambulant Patients With Duchenne Muscu ...	Duchenne Muscular Dystrophy	Drug: Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]	Rare Disease Research, LLC	Sarepta Therapeutics, Inc.	Terminated	7 Years	N/A	Male	2	Phase 4	United States
4	EUCTR2017-004625-32-SE (EUCTR)	17/06/2020	09/08/2018	A long-term extension study of a new investigational medicinal product for the treatment of Duchenne ...	Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clin ...	Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping MedDRA version: 20.0;Lev ...	Product Name: SRP-4045 Product Code: SRP-4045 INN or Proposed INN: CASIMERSEN Other descriptive name: P ...	Sarepta Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	260	Phase 3	United States;Czechia;Spain;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Belgium;Poland; ...
5	NCT04179409 (ClinicalTrials.gov)	February 18, 2020	12/8/2019	A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golod ...	A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golod ...	Duchenne Muscular Dystrophy	Drug: Casimersen;Drug: Eteplirsen;Drug: Golodirsen	Kevin Flanigan	Sarepta Therapeutics, Inc.	Active, not recruiting	6 Months	N/A	Male	3	Phase 2	United States
6	EUCTR2015-002069-52-DK (EUCTR)	26/11/2019	25/07/2019	A research study of a new investigational medicinal product for the treatment of Duchenne Muscular D ...	A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the E ...	Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping MedDRA version: 20.0;Le ...	Product Name: SRP-4045 Product Code: SRP-4045 INN or Proposed INN: Casimersen Other descriptive name: P ...	Sarepta Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	222	Phase 3	Serbia;United States;Taiwan;Greece;Spain;Ukraine;Ireland;Israel;Russian Federation;Italy;France;Aust ...
7	EUCTR2017-004625-32-FR (EUCTR)	05/02/2019	23/07/2018	A long-term extension study of a new investigational medicinal product for the treatment of Duchenne ...	Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clin ...	Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping MedDRA version: 20.0;Lev ...	Product Name: SRP-4045 Product Code: SRP-4045 INN or Proposed INN: CASIMERSEN Other descriptive name: P ...	Sarepta Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	260	Phase 3	United States;United Kingdom;Spain;Canada;Czech Republic;Sweden;Belgium;Ireland;Finland;Poland;Italy ...
8	EUCTR2017-004625-32-BE (EUCTR)	20/12/2018	10/09/2018	A long-term extension study of a new investigational medicinal product for the treatment of Duchenne ...	Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clin ...	Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping MedDRA version: 20.0;Le ...	Product Name: SRP-4045 Product Code: SRP-4045 INN or Proposed INN: CASIMERSEN Other descriptive name: P ...	Sarepta Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	150	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;Finland;Spain;Ireland;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Poland; ...
9	EUCTR2017-004625-32-ES (EUCTR)	07/09/2018	10/09/2018	A long-term extension study of a new investigational medicinal product for the treatment of Duchenne ...	Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clin ...	Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53Skipping MedDRA version: 20.0;Lev ...	Product Name: SRP-4045 Product Code: SRP-4045 INN or Proposed INN: CASIMERSEN Other descriptive name: P ...	Sarepta Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	150	Phase 3	United States;Finland;Spain;Ireland;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Poland; ...
10	EUCTR2015-002069-52-BG (EUCTR)	06/08/2018	11/06/2018	A research study of a new investigational medicinal product for the treatment of Duchenne Muscular D ...	A Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the E ...	Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping MedDRA version: 20.0;Le ...	Product Name: SRP-4045 Product Code: SRP-4045 INN or Proposed INN: Casimersen Other descriptive name: P ...	Sarepta Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	222	Phase 3	United States;Serbia;Taiwan;Greece;Spain;Ukraine;Ireland;Israel;Russian Federation;Italy;France;Aust ...

First Previous1 2Next Last